
If you had been weighing Recursion Pharmaceuticals in late 2025 and decided to stay on the sidelines, the past twelve months may look different now that the dust has settled. Holding Recursion Pharmaceuticals over the past year would have meant a 24.6% loss, including dividends. With some analysts focusing on AI driven drug discovery and others emphasizing heavy R&D burn and regulatory risk at the outset, which of those on record concerns or assumptions would you have scrutinized most closely before committing capital?
A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.
This theme extends beyond Recursion Pharmaceuticals. See which of 36 healthcare AI stocks may still merit a closer look.
The shares cost US$4.51 at the start of the period, so any view on Recursion Pharmaceuticals hinged on whether its AI story justified paying above or below that point.
On the bullish side, one Simply Wall St Narrative saw Fair Value at US$6.54, 45% above the start price, based on the Recursion OS 2.0 platform using advanced AI and large proprietary datasets to improve R&D efficiency and attract big pharma partners.
The bearish Narrative put Fair Value at US$3, 33% below the start price, stressing heavy R&D burn, early stage programs and regulatory scrutiny of healthcare AI as key threats to future cash flows and partnership driven revenue.
Recursion Pharmaceuticals then reported Q3 2026 results with revenue of US$18.552 million and a net loss of US$119.036 million, compared with Q3 2025 revenue of US$5.175 million and a loss of US$162.253 million. That combination supported the bullish AI efficiency story on R&D discipline, yet profitability remained unproven, so the evidence cut both ways for the original fair value debate.
The lesson for you is clear. When a biotech leans on an AI productivity pitch, test it against two figures over time: cash operating expense trends and absolute losses in quarterly filings, rather than headlines about platforms or partnerships.
Recursion Pharmaceuticals trades at US$3.55, down 24.6% over the past year, while the current bullish Narrative sees Fair Value above that level based on its view of the business.
According to Talos, a Simply Wall St Community investor who wrote the Narrative, your call today hinges on whether an AI driven pipeline and partnership model can translate into durable commercial revenue. The key assumption is that current clinical momentum and cash discipline eventually support a sustainable, self funded drug portfolio.
"Recursion Pharmaceuticals is currently at a critical inflection point. For years, the company was viewed as a "science project", a high-tech platform promising to revolutionize drug discovery with AI."
One Narrative disagrees with today's price. → See where this Narrative says Recursion Pharmaceuticals should trade
This company's disappointment is already part of the story. Your next idea could come from looking where the price and the possibilities still seem far apart. Here are three companies priced below our estimates.
That is three of the list. See every one of the 35 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com